Victoria's research is focused on finding synergy between the metronomic therapy topotecan/etoposide and the mTor inhibitor sirolimus on medulloblastoma cell lines of various subtypes. CRISPR-Cas9-edited cells with mutations specific to patients with medulloblastoma are also used to test this therapy. In the near future, it is planned to study the molecular mechanisms of cell death with a combination of drugs.